Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers"

Clin Pharmacol Ther. 2014 Mar;95(3):252. doi: 10.1038/clpt.2013.239. Epub 2013 Dec 17.

Authors

S M Markova¹, J B Schwartz², D L Kroetz¹

Affiliations

¹ Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
² Department of Medicine, University of California, San Francisco, San Francisco, California, USA.

PMID: 24346422
DOI: 10.1038/clpt.2013.239

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Comment

MeSH terms

Aryl Hydrocarbon Hydroxylases / genetics*
Chemical and Drug Induced Liver Injury / etiology*
Endothelin Receptor Antagonists*
Female
Humans
Hypertension, Pulmonary / drug therapy*
Male
Sulfonamides / adverse effects*

Substances

Endothelin Receptor Antagonists
Sulfonamides
Aryl Hydrocarbon Hydroxylases

Grants and funding

GM061390/GM/NIGMS NIH HHS/United States